Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.
The company believes that blood-based exome sequencing can increase the applicability of its Signatera assays and could serve as a reflex to interrogate detected recurrences.
The investment bank gave the liquid biopsy company a price target of $90 and said that it views Guardant as the field leader.
OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
As of July 1, the Guardant360 test will be considered medically necessary for aiding therapy selection in advanced lung cancer for health plan members of EviCore.
The center received a response to its initial submission to the NY State Department of Health in February and will re-submit by the end of this month.
A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.
The company is seeking NY State approval for its lab, which would allow it to offer both tests as LDTs, hopefully by the end of this year or early next.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."